DaVita
DaVita is the largest dialysis provider in the United States, operating approximately 2,657 outpatient dialysis centers serving around 281,100 patients with end-stage renal disease (ESRD). The company provides in-center hemodialysis, home dialysis, and related laboratory services, forming one half of a duopoly with Fresenius Medical Care that controls roughly 77% of the U.S. dialysis market.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
DLJ Merchant Banking acquired the predecessor company in a leveraged buyout, founding Total Renal Care as an LBO-backed dialysis consolidation vehicle. The for-profit dialysis industry was fragmented with independent clinics holding over 80% market share, and lock-in from dialysis necessity existed but monopoly pricing power had not yet concentrated. Early extraction was limited to the LBO debt structure and aggressive acquisition posture.
After the disastrous $1.3 billion Renal Treatment Centers acquisition collapsed integration systems and drove the company to near-bankruptcy with $1.5 billion in debt and 52% staff turnover, Kent Thiry took over as CEO. The turnaround stabilized operations and improved clinical quality, but the underlying consolidation-driven business model remained. The SEC investigation was closed without charges in 2005, and governance improved under new leadership.
The $3.1 billion acquisition of Gambro Healthcare doubled DaVita's clinic count and forged a duopoly with Fresenius controlling roughly 59% of the market. The FTC required divestiture of 70 clinics across 35 markets but the structural transformation was irreversible. Physician kickback schemes began in earnest as DaVita used below-market joint venture stakes and noncompete agreements to lock in referrals. Commercial insurance exploitation deepened as market power grew.
Medicare's ESRD bundled payment system eliminated profitable separate drug billing, intensifying DaVita's drive to maximize commercial payer mix. Berkshire Hathaway began accumulating shares. The $55 million Epogen overbilling settlement and the $4.42 billion HealthCare Partners acquisition signaled both regulatory exposure and diversification ambition. The duopoly's market share continued climbing through systematic acquisition of independent clinics.
The $389 million kickback settlement (2014) and $495 million Medicare fraud settlement (2015) brought DaVita's cumulative federal payouts near $1 billion. Rather than reforming, the company accelerated shareholder extraction: buybacks began in earnest and would total billions over the next decade. The American Kidney Fund insurance steering mechanism was now generating an estimated 60% of pre-tax profits. The company simultaneously fought California staffing regulations and fired a whistleblower employee who testified for SB 349.
DaVita sold its Medical Group to UnitedHealth for $4.3 billion, refocusing entirely on dialysis and funneling sale proceeds into share buybacks exceeding $5 billion in 2019-2020 alone. Kent Thiry departed and was later indicted (though acquitted) for no-poach conspiracy. The company spent $67-68 million defeating California Prop 8 and Prop 23, while the D.C. attorney general investigated the AKF charity donation scheme. Union-busting spending reached $7 million over four years as staffing deteriorated.
Multiple enforcement actions converge simultaneously: the FTC investigates noncompete practices via CIDs, a UFCW class action alleges market collusion, Senator Blumenthal demands FTC action, and a JAMA study confirms dialysis as the most concentrated healthcare sector. Workers struck 37 clinics over unsafe staffing. A ransomware breach exposed 2.7 million patient records. The MATCH-D quota class action, $34 million kickback settlement, and $3.8 million data privacy settlement compound the regulatory exposure. Buybacks exceeded $1.4 billion in 2024 at a 299:1 CEO pay ratio.
Alternatives
DaVita and Fresenius Medical Care form a duopoly controlling roughly 77% of U.S. dialysis centers. Patients requiring thrice-weekly hemodialysis are limited to facilities within driving distance that accept their insurance. In 32.5% of the U.S. population's areas, the only available providers are DaVita or Fresenius. Independent clinics exist but are too fragmented and geographically sparse to serve as a viable alternative for most patients.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (50 events)
DLJ Merchant Banking Acquires Majority Stake via LBO
DLJ Merchant Banking Partners acquired 70% of Medical Ambulatory Care for $75.5 million in a leveraged buyout, renaming it Total Renal Care Holdings, Inc. The LBO-backed consolidation strategy set the template for rapid acquisition of independent dialysis clinics that would define the next three decades.
Total Renal Care IPO Raises $107 Million
Total Renal Care Holdings went public, raising $107 million. The IPO funded an aggressive acquisition spree that would grow the company from fewer than 40 facilities to nearly 500 within five years, establishing the rollup-consolidation business model.
Disastrous $1.3 Billion Acquisition of Renal Treatment Centers
Total Renal Care acquired Renal Treatment Centers for $1.3 billion in stock, doubling its patient and staff base overnight. The integration overwhelmed the company's billing systems — a 600-person billing office in Tacoma could not handle the expanded network. Accounts went uncollected, patients were billed incorrectly, and debt surged to $1.5 billion.
Rapid Clinic Rollup Creates Geographic Patient Lock-In
By mid-1998, Total Renal Care operated nearly 500 dialysis facilities across 33 states through aggressive acquisition of independent clinics. Because ESRD patients require thrice-weekly hemodialysis sessions lasting 3-4 hours each, they are effectively locked into the nearest facility within reasonable driving distance. As Total Renal Care absorbed independents, patients in acquired markets lost their ability to switch providers, creating de facto geographic lock-in even before the duopoly consolidated.
CEO and CFO Resign Amid Near-Bankruptcy
Total Renal Care's CEO and CFO resigned as the company teetered near bankruptcy with $1.5 billion in debt, a 52% annual employee turnover rate, and stock that had plunged from over $30 to under $5. The SEC opened an investigation into accounting practices. The company could barely make payroll.
Kent Thiry Appointed CEO, Begins Turnaround
Kent J. Thiry, a 43-year-old former Bain & Company consultant, was appointed CEO of the near-bankrupt Total Renal Care. Over the next five years he stabilized the company, cutting employee turnover from 52% to the low 20s, turning a $147 million loss (1999) into $222 million net income (2004), and growing revenue from $1.5 billion to $2.3 billion.
Company Rebrands to DaVita
More than 600 company leaders voted to rename Total Renal Care to DaVita, an Italian phrase meaning 'to give life.' The rebrand accompanied a cultural overhaul emphasizing values-based management and community identity, though the underlying business model of consolidation-driven growth remained intact.
Drug Wastage Fraud Scheme Begins at DaVita Clinics
Beginning in 2003, DaVita clinics implemented systematic practices to maximize injectable drug waste and bill Medicare for unused portions. Whistleblowers later alleged DaVita created 'dosing grids' for Zemplar, Venofer, and other injectables designed to ensure vials were only partially used, with the remainder discarded and billed to government programs. Staff were trained in 'how to manipulate the system,' and Amgen representatives were allowed to review patient charts to push higher Epogen dosing.
DaVita Resumes Clinic Acquisitions After Turnaround Stabilization
After pausing acquisitions during 2000-2002 to restructure its balance sheet, DaVita resumed acquiring independent dialysis clinics, purchasing RMS Lifeline's 12 vascular access clinics from Baxter Healthcare and signing agreements for additional center acquisitions. By late 2004, DaVita acquired Physicians Dialysis Inc. for $150 million, adding 24 centers and 1,700 patients. These sub-threshold acquisitions escaped federal merger review, methodically reducing local competition.
Kent Thiry's Turnaround Drives Shareholder Returns as Physician Kickback Targeting Begins
Under Thiry, DaVita converted a $417 million loss (1999) into $222 million net income (2004) on $2.3 billion revenue, growing market capitalization from roughly $200 million to over $5 billion. Thiry's compensation rose in tandem through stock options and equity awards. Meanwhile, DaVita began identifying 'winning' nephrologist practices — those with large patient populations who were 'young and in debt' — to target with below-market joint venture stakes in exchange for patient referrals, binding all physicians in a practice group through noncompete agreements.
Gambro Acquisition Creates Dialysis Duopoly
DaVita acquired Gambro Healthcare, the third-largest U.S. dialysis provider with 565 clinics serving 43,200 patients, for $3.1 billion. The deal effectively created a duopoly with Fresenius, with the two companies controlling roughly 59% of facilities. The FTC identified 35 markets where competition would be lessened, with 11 facing monopoly conditions, and required divestiture of 70 clinics.
FTC Consent Order Requires 70-Clinic Divestiture
As a condition of the Gambro acquisition, DaVita divested 69 dialysis clinics and ended two management contracts across 35 markets to Renal Advantage. The order prohibited DaVita from soliciting divested clinic patients for two years and required FTC notification before any future acquisitions in affected markets. Despite divestitures, the deal cemented a duopoly structure.
FDA Issues Black Box Warning on ESAs Amid DaVita Overprescribing Concerns
The FDA issued a black box warning on erythropoiesis-stimulating agents (Epogen/Aranesp), finding that targeting hemoglobin above 12 g/dL increased death, heart attacks, and strokes. DaVita facilities had only 30% of patients at safe hemoglobin levels compared to 80% at nonprofit competitor DCI, reflecting the financial incentive to overdose ESAs — each vial generated separate Medicare reimbursement before bundled payment reform. The warning signaled the agency's concern about profit-driven drug administration in dialysis.
DaVita Board Authorizes $250 Million Stock Repurchase Program
DaVita's board of directors authorized a $250 million share repurchase program, marking the company's first significant capital return to shareholders. Under Kent Thiry, whose total compensation reached $14.1 million by 2010 (including $4.7 million in stock options and $4.8 million in stock awards), DaVita began establishing the buyback-centric capital allocation strategy that would later consume billions annually. The program signaled the shift from reinvestment toward shareholder extraction.
For-Profit Dialysis Chains Staff Fewer RNs Than Nonprofits
Research published on dialysis facility staffing found that DaVita and other large for-profit chains employed significantly fewer registered nurses and licensed practical nurses per patient than nonprofit competitor DCI, substituting lower-cost patient care technicians. CMS changed federal regulations in 2008 to require at least one RN present in dialysis facilities — a minimal standard that large chains met while maintaining high patient-to-staff ratios that compressed labor costs.
Kickback Scheme to Physicians Exposed by Whistleblower
Former DaVita senior financial analyst David Barbetta filed a qui tam lawsuit alleging DaVita identified nephrologists with large patient populations, targeted 'winning' practices that were 'young and in debt,' and offered below-market joint venture stakes to lock in patient referrals. Noncompete agreements bound all physicians in a practice group, preventing them from directing patients elsewhere.
Medicare ESRD Bundled Payment System Takes Effect
CMS implemented the ESRD Prospective Payment System, bundling previously separate payments for drugs, labs, and supplies into a single per-treatment rate of $229.63. Over 95% of providers, including DaVita, adopted the new system immediately rather than phasing in over four years. The reform shifted financial incentives, reducing profitable drug overbilling but intensifying pressure to maximize commercial payer mix.
Berkshire Hathaway Begins Accumulating DaVita Shares
Ted Weschler, a Berkshire Hathaway portfolio manager, began building a large position in DaVita shares during Q4 2011. Berkshire would eventually accumulate over 45% of outstanding shares. In May 2013, Berkshire agreed to a standstill capping its stake at 25%, though this limit was later relaxed as DaVita's aggressive buyback program concentrated ownership.
No-Poach Agreements with Competitor Healthcare Companies Begin
Beginning in 2012 and continuing through 2019, DaVita and CEO Kent Thiry allegedly entered into agreements with Surgical Care Associates, Hazel Health, and Radiology Partners not to recruit each other's senior-level employees. The DOJ would later characterize this as a conspiracy to suppress employee mobility and wages across the healthcare labor market. These agreements operated alongside medical director noncompete clauses to systematically restrict labor competition in markets where DaVita was dominant.
$55 Million Settlement for Epogen Overbilling
DaVita settled a whistleblower lawsuit for $55 million, resolving allegations it administered 'overfill' quantities of the anemia drug Epogen to patients and fraudulently sought reimbursement from Medicare for the unused portions. The case was brought by former Amgen employee Ivey Woodard. This was the first of three major federal settlements totaling nearly $1 billion.
$4.42 Billion Acquisition of HealthCare Partners
DaVita acquired HealthCare Partners, the nation's largest operator of medical groups and physician networks, for $4.42 billion ($3.66 billion cash plus 9.38 million shares). The acquisition diversified DaVita into integrated care, creating DaVita HealthCare Partners Inc. The deal was partly funded by debt, adding leverage to an already capital-intensive business.
AKF Insurance Steering Scheme Scales Up Under Pricing Opacity
By 2013, DaVita and Fresenius provided nearly 80% of the American Kidney Fund's total funding. The circular mechanism — donating to AKF, which paid patients' commercial insurance premiums, generating 3-4x higher reimbursements — operated with minimal disclosure. Patients receiving insurance counseling through the program did not understand the financial incentives behind the recommendations. The pricing gap between Medicare's bundled rate (approximately $230 per treatment) and commercial rates ($800-$1,200) was not publicly reported, enabling systematic exploitation of information asymmetry.
CMS Reports Rising Patient-to-Staff Ratios at For-Profit Dialysis Chains
Research examining 2010-2013 staffing data found mean patient-to-nurse ratios of 15-16 patients per RN at for-profit dialysis chains. DaVita relied heavily on lower-cost patient care technicians while minimizing registered nurse staffing. Studies documented that higher patient-to-RN ratios were associated with increased dialysis hypotension episodes, skipped treatments, shortened treatment times, and patient complaints — outcomes directly linking staffing decisions to patient care quality erosion.
$389 Million Settlement for Physician Kickbacks
DaVita paid $389 million to resolve allegations that between 2005 and 2014 it paid kickbacks to nephrologists through below-market joint venture stakes to secure patient referrals. The DOJ found DaVita targeted 'winning' physician practices — those with large patient populations who were 'young and in debt' — and required noncompete agreements binding all group physicians regardless of their involvement.
$495 Million Settlement for Medicare Drug Wastage Fraud
DaVita paid $495 million ($450 million plus $45 million in legal fees) to settle False Claims Act violations for billing Medicare and Medicaid for unused portions of Zemplar, Venofer, and other injectable drugs between 2003 and 2010. Whistleblowers Dr. Alon Vainer and Nurse Daniel Barbir alleged DaVita created 'dosing grids' designed to maximize drug waste. This was DaVita's third major federal settlement since 2012, bringing total payouts to nearly $1 billion.
Insurance Steering Lawsuit Alleges Charity-Funded Profit Loop
A federal lawsuit alleged DaVita steered poor dialysis patients to commercial insurance plans to inflate revenue, exploiting the American Kidney Fund premium assistance program. DaVita and Fresenius provided nearly 80% of AKF's funding; an estimated 60% of DaVita's pre-tax profit came from patients whose premiums were funded by the charity. Approximately 4,000 patients receiving AKF-funded premiums generated roughly $450 million in annual operating income.
FTC Requires Seven-Clinic Divestiture in $358 Million Renal Ventures Acquisition
The FTC required DaVita to divest seven dialysis clinics — five in New Jersey (Brick, Clifton, Somerville, Succasunna, Trenton) and two near Dallas (Denton, Frisco) — as a condition of its $358 million acquisition of Renal Ventures Management's 38 centers. In several markets, the acquisition represented a merger to monopoly or reduction from three competitors to two. The FTC barred DaVita from contracting with divested clinic medical directors for three years, acknowledging that noncompete agreements were a tool of market entrenchment.
DaVita Fires Employee After Capitol Testimony on Patient Safety
DaVita terminated a 16-year employee less than one day after he gave testimony at the California State Capitol in support of SB 349, the Dialysis Patient Safety Act that would have set nurse-to-patient ratios of 1:8 and technician-to-patient ratios of 1:3. Three additional employees at the same Moreno Valley clinic were also fired. The bill was ultimately withdrawn for lack of legislative support.
DaVita Spends $67 Million to Defeat California Proposition 8
DaVita contributed approximately $67 million to defeat California Proposition 8, which would have capped dialysis clinic profits at 15% above patient care costs. Combined with Fresenius, the industry spent $111 million opposing the measure — a national record for ballot measure spending at the time. The proposition was defeated with 60% voting no.
CEO Transition: Rodriguez Succeeds Thiry After 20 Years
DaVita announced Javier J. Rodriguez as CEO effective June 1, 2019, succeeding Kent Thiry who had led the company since 1999. Rodriguez had been with DaVita since 1998 and served as CEO of DaVita Kidney Care since 2014. Thiry transitioned to executive chairman. The leadership change occurred as DaVita was refocusing on pure-play dialysis following the DaVita Medical Group sale.
DaVita Medical Group Sold to UnitedHealth for $4.3 Billion
Optum, a UnitedHealth Group subsidiary, completed its $4.3 billion acquisition of DaVita Medical Group, which managed physician networks and medical groups. The FTC required divestiture of HealthCare Partners of Nevada to Intermountain Healthcare, as the combined entity would have controlled over 80% of managed care provider services to Medicare Advantage insurers in Las Vegas. The sale refocused DaVita entirely on dialysis extraction.
D.C. Attorney General Investigates AKF Charity Connections
Washington D.C.'s attorney general requested information from DaVita and Fresenius concerning antitrust concerns related to the American Kidney Fund. The investigation examined whether the companies' donations to the charity, which then paid patients' commercial insurance premiums, constituted anti-competitive behavior. DaVita and Fresenius provided nearly 80% of AKF's total funding while receiving the highest-rate reimbursements for AKF-funded patients.
DaVita Spends $68 Million to Defeat California Proposition 23
DaVita contributed approximately $68 million to defeat California Proposition 23, the second consecutive ballot measure seeking to regulate dialysis clinics. Prop 23 would have required a physician on-site during all treatment hours. Combined industry spending exceeded $105 million against the measure. It was defeated with 63% voting no.
DaVita Executes $2.35 Billion Single-Quarter Stock Buyback
DaVita repurchased $2.35 billion in stock in Q4 2020 alone, funded largely by the $4.3 billion DaVita Medical Group sale proceeds. The company's total buybacks for 2019-2020 exceeded $5 billion. As share count contracted, Berkshire Hathaway's passive ownership percentage rose toward 40%, concentrating shareholder returns among fewer holders while clinical staff wages remained flat.
DOJ Indicts DaVita and Kent Thiry for No-Poach Conspiracy
The Department of Justice criminally indicted DaVita Inc. and former CEO Kent Thiry under the Sherman Act for allegedly conspiring with Surgical Care Associates, Hazel Health, and Radiology Partners not to recruit each other's employees between 2012 and 2019. This was the first criminal prosecution of no-poach agreements under the 1890 antitrust law, signaling systematic suppression of employee mobility.
FTC Imposes Prior Approval Requirements After Utah Acquisition
The FTC settled charges that DaVita's proposed acquisition of University of Utah Health's 18 dialysis clinics would reduce competition in the Provo, Utah market. DaVita was required to divest three clinics to Sanderling Renal Services, prohibited from enforcing noncompete agreements with employees, and ordered to seek FTC prior approval before any future dialysis clinic acquisitions in Utah for ten years.
Jury Acquits DaVita and Thiry on All No-Poach Counts
A federal jury found DaVita and former CEO Kent Thiry not guilty on all counts in the landmark DOJ criminal no-poach prosecution after a two-week trial. Despite the acquittal, trial testimony revealed systematic practices of coordinating employee non-solicitation with competitor health care companies. The prosecution established that the agreements existed, even if they did not meet the criminal conspiracy standard.
DaVita Spends $52.7 Million to Defeat Third California Ballot Measure
DaVita contributed $52.7 million to defeat Proposition 29, the third consecutive California ballot measure targeting dialysis clinics. Prop 29 would have required a physician, nurse practitioner, or physician assistant on-site during treatment hours. The industry's combined spending exceeded $86 million against the measure. Across three cycles (2018-2022), DaVita and Fresenius spent over $170 million defeating regulatory requirements in California alone.
Congressional Press Conference Demands Dialysis Company Accountability
SEIU-UHW dialysis caregivers held a press conference joined by Congressmembers Lofgren, Schiff, and Porter demanding accountability from DaVita and Fresenius over staffing, patient safety, and the companies' billion-dollar federal contracts. Workers testified about chronic understaffing, patient-to-technician ratios as high as 15:1, and conditions where treatment errors could be fatal.
Dialysis Caregivers Picket DaVita Clinics Across California
SEIU-UHW members picketed DaVita clinics over staffing shortages, patient care problems, and anti-union activity. Workers reported years of understaffing creating dangerous conditions for patients requiring life-sustaining treatment. DaVita had spent nearly $7 million on union-busting consultants from 2017-2020 and had reportedly closed at least one facility where organizing activity occurred.
FTC Issues Two CIDs Investigating Dialysis Noncompetes
The Federal Trade Commission issued two Civil Investigative Demands to DaVita covering the period from January 2016 to present, seeking information about restrictive covenants and noncompete agreements with medical directors. The investigation focused on how noncompete clauses prevented nephrologists from joining competitors or establishing independent clinics, effectively blocking new market entrants.
Board Authorizes Additional $2 Billion in Share Repurchases
DaVita's board of directors increased its share repurchase authorization by $2 billion, bringing cumulative authorizations to approximately $8 billion. The company had already repurchased $1.386 billion in 2024 alone, with CEO Rodriguez earning $21.8 million (299:1 pay ratio) while dialysis technicians earned $35,000-$45,000 annually.
$34 Million Kickback Settlement Filed by Former COO
DaVita paid $34.5 million to resolve False Claims Act allegations brought by former DaVita Kidney Care COO Dennis Kogod. The settlement addressed kickbacks to a competitor to refer Medicare patients' prescriptions to DaVita Rx, kickbacks to nephrologists for patient referrals, and improper payments to a nephrology practice including a $50,000 payment for a position the practice declined to staff.
Workers at 37 DaVita Clinics Launch Six-Day Strike
Nearly 1,000 healthcare workers at 37 DaVita dialysis clinics across California launched six-day unfair labor practice strikes. SEIU-UHW had filed 77 unfair labor practice charges against dialysis companies including DaVita. Workers cited years of unsafe staffing, low wages, and anti-union retaliation. DaVita had spent nearly $7 million on union-busting consultants from 2017-2020.
$3.8 Million Settlement for Facebook Pixel Patient Data Sharing
A federal court granted final approval of a $3.8 million settlement resolving class action claims that DaVita shared patient health data with Facebook, Google, and other third parties through Meta Pixel and Conversions API tracking tools installed on its websites and patient portals between 2017 and 2023, affecting over 600,000 patients who never consented to the disclosure.
Class Action Alleges MATCH-D Quota Program Pressured Patients into PD
A class action lawsuit alleged DaVita used a quota-driven sales program called MATCH-D to pressure patients into home peritoneal dialysis, prioritizing enrollment numbers over clinical appropriateness. Staff who failed to meet quotas faced 'retaliation, intimidation, and humiliation.' Patients reported being 'relentlessly bombarded' with exaggerated PD benefits while risks including peritonitis and decreased transplant eligibility were minimized.
Senator Blumenthal Presses FTC on Dialysis Market Concentration
U.S. Senator Richard Blumenthal called on the FTC to take 'robust enforcement action' against DaVita and Fresenius, noting 'just two companies control more than three-fourths of the dialysis market.' He requested briefings on the ongoing noncompete investigation, DaVita's compliance with its 2022 consent order restricting acquisitions, and any other antitrust issues in the dialysis industry.
Ransomware Attack Exposes Data of 2.7 Million Patients
The Interlock ransomware group breached DaVita's network between March 24 and April 12, 2025, exfiltrating over 20 terabytes of data including 200+ million rows of patient records. Compromised information included names, SSNs, medical records, insurance details, and financial data for 2.7 million individuals. When DaVita refused to pay the ransom, 1.5 terabytes of data was published on the dark web. The incident cost $13.5 million in Q2 2025.
UFCW Files Antitrust Class Action Alleging DaVita-Fresenius Collusion
The benefits fund for UFCW Local 1776 filed a class action in the U.S. District Court for the District of Colorado alleging DaVita and Fresenius conspired to allocate markets, protect supracompetitive profits, and collude with the American Kidney Fund to steer patients to lucrative private insurance. The suit claims prices 'would have been significantly lower' absent the conspiracy. DaVita and Fresenius moved to dismiss, arguing similar pricing is a natural outcome of concentration.
JAMA Study Confirms Dialysis Is Most Concentrated Healthcare Sector
A JAMA Health Forum study documented that between 2005 and 2019, DaVita and Fresenius increased their combined facility share from 59.1% to 77.1%, while independent centers declined from 20.4% to 10.6%. Markets with only one large chain had $495 higher average commercial prices and $565 higher medical director compensation per patient. The study concluded dialysis is 'the most concentrated of all health care sectors.'
Evidence (41 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (4 entries)
Fixed Medicare rate ($239.33 was 2020 rate, updated to $271.02 CY 2024), Q1 2025 buybacks ($510M corrected to $550M), CA ballot spending ($143M corrected to $170M+)